Statera Biopharma, Inc. (STAB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2021 | -98.34 Million USD | 468.32% |
| 2020 | -10.5 Million USD | -273.17% |
| 2019 | -2.81 Million USD | 41.37% |
| 2018 | -4.79 Million USD | 14.3% |
| 2017 | -5.6 Million USD | 11.88% |
| 2016 | -6.35 Million USD | 41.1% |
| 2015 | -10.79 Million USD | 99.93% |
| 2014 | -14.42 Billion USD | 37.5% |
| 2013 | -23.07 Billion USD | 23.2% |
| 2012 | -30.04 Billion USD | -19.68% |
| 2011 | -25.1 Billion USD | -195636.56% |
| 2010 | -12.82 Million USD | 99.8% |
| 2009 | -6.38 Billion USD | 55.51% |
| 2008 | -14.34 Billion USD | -53037.88% |
| 2007 | -26.99 Million USD | -273.78% |
| 2006 | -7.22 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 Q2 | -2.85 Million USD | 56.85% |
| 2022 Q1 | -6.61 Million USD | 91.43% |
| 2022 Q3 | -1.54 Million USD | 45.81% |
| 2021 Q4 | -77.18 Million USD | -700.32% |
| 2021 Q2 | -6.32 Million USD | -21.75% |
| 2021 Q3 | -9.64 Million USD | -52.51% |
| 2021 FY | 38.67 Million USD | 468.32% |
| 2021 Q1 | -5.19 Million USD | -40.11% |
| 2020 Q4 | -3.7 Million USD | 39.92% |
| 2020 Q1 | -111.91 Thousand USD | 0.0% |
| 2020 Q2 | -592.19 Thousand USD | -429.12% |
| 2020 FY | -10.5 Million USD | -273.17% |
| 2020 Q3 | -6.17 Million USD | -942.0% |
| 2019 Q3 | -518.39 Thousand USD | 32.82% |
| 2019 FY | -2.81 Million USD | 41.37% |
| 2019 Q1 | -790.17 Thousand USD | 0.0% |
| 2019 Q2 | -771.6 Thousand USD | 2.35% |
| 2018 Q3 | -1.26 Million USD | -18.7% |
| 2018 FY | -4.79 Million USD | 14.3% |
| 2018 Q1 | -1.83 Million USD | 0.0% |
| 2018 Q2 | -1.06 Million USD | 41.83% |
| 2017 FY | -5.6 Million USD | 11.88% |
| 2017 Q2 | -1.57 Million USD | 3.02% |
| 2017 Q1 | -1.61 Million USD | 0.0% |
| 2017 Q3 | -1.19 Million USD | 23.76% |
| 2016 Q3 | -714.13 Thousand USD | 52.21% |
| 2016 Q2 | -1.49 Million USD | 35.38% |
| 2016 Q1 | -2.31 Million USD | 0.0% |
| 2016 FY | -6.35 Million USD | 41.1% |
| 2015 FY | -10.79 Million USD | 99.93% |
| 2015 Q3 | -2.81 Million USD | 1.18% |
| 2015 Q2 | -2.85 Million USD | 13.91% |
| 2015 Q1 | -3.31 Million USD | 0.0% |
| 2014 Q3 | -3.43 Million USD | 14.3% |
| 2014 Q1 | -3.51 Million USD | 0.0% |
| 2014 FY | -14.42 Billion USD | 37.5% |
| 2014 Q2 | -4.01 Million USD | -14.02% |
| 2013 Q3 | -5.85 Million USD | 13.58% |
| 2013 Q2 | -6.77 Million USD | 9.01% |
| 2013 FY | -23.07 Billion USD | 23.2% |
| 2013 Q1 | -7.44 Million USD | 0.0% |
| 2012 Q3 | -7.84 Million USD | 14.41% |
| 2012 Q2 | -9.16 Million USD | -22.45% |
| 2012 Q1 | -7.48 Million USD | 0.0% |
| 2012 FY | -30.04 Billion USD | -19.68% |
| 2011 Q3 | -6.96 Million USD | -5.04% |
| 2011 Q1 | -5.11 Million USD | 0.0% |
| 2011 FY | -25.1 Billion USD | -195636.56% |
| 2011 Q2 | -6.62 Million USD | -29.64% |
| 2010 Q3 | -967.7 Thousand USD | 63.07% |
| 2010 FY | -12.82 Million USD | 99.8% |
| 2010 Q1 | -1.45 Million USD | 0.0% |
| 2010 Q2 | -2.62 Million USD | -79.87% |
| 2009 FY | -6.38 Billion USD | 55.51% |
| 2009 Q2 | -2.42 Million USD | -84.35% |
| 2009 Q1 | -1.31 Million USD | 0.0% |
| 2009 Q3 | -1.09 Million USD | 54.99% |
| 2008 Q1 | -4.06 Million USD | 0.0% |
| 2008 FY | -14.34 Billion USD | -53037.88% |
| 2008 Q3 | -2.87 Million USD | 28.16% |
| 2008 Q2 | -4 Million USD | 1.65% |
| 2007 Q3 | -17.01 Million USD | -109.71% |
| 2007 Q1 | -4.1 Million USD | 0.0% |
| 2007 FY | -26.99 Million USD | -273.78% |
| 2007 Q2 | -8.11 Million USD | -97.58% |
| 2006 FY | -7.22 Million USD | 0.0% |
| 2006 Q2 | -1.28 Million USD | 0.0% |
| 2006 Q3 | -1.66 Million USD | -29.29% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -19862.448% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -933.24% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -227.889% |
| Biora Therapeutics, Inc. | -67.14 Million USD | -46.469% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -520.74% |
| Better Therapeutics, Inc. | -38.26 Million USD | -157.027% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -133.74% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -721.585% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -190.58% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -185.725% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 9.332% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -4782.277% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -189.229% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -109.461% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -7092.103% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -393.216% |
| Molecular Templates, Inc. | -10.46 Million USD | -839.65% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -599.911% |
| NexImmune, Inc. | -29.19 Million USD | -236.881% |
| Orgenesis Inc. | -53.63 Million USD | -83.354% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -91.726% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -125954.325% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -509.118% |
| Scopus BioPharma Inc. | -11.71 Million USD | -739.478% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 80.5% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -1325.686% |
| Trevena, Inc. | -35.28 Million USD | -178.689% |
| Vaxxinity, Inc. | -58.28 Million USD | -68.729% |
| Vaccinex, Inc. | -22.88 Million USD | -329.73% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -9293.111% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | -93.999% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -1254.036% |